YOLFTbeta
Zelira Therapeutics Ltd

Zelira Therapeutics Ltd

ZLD · AU · Healthcare / Biotechnology

0.50AUD+0.00 (0.00%)

Price History

Full chart

Market Stats

Previous Close0.50
Open0.50
Day Range0.50 – 0.50
52-Week Range0.31 – 1.15
Volume0
Market Cap6.57M
P/E (TTM)0.00
Forward P/E5.78
EPS-0.32
Dividend Yield0.00%
Beta0.61
50-Day Avg0.50
200-Day Avg0.5126

About

Zelira Therapeutics Limited, a biopharmaceutical company, engages in the research, development, and commercialization of cannabinoid-based medicines for the treatment of various medical conditions in Australia and the United States. It offers formulations under the HOPE brand in Australia, Washington, Pennsylvania, and Louisiana, as well as develops ZENIVOL, a cannabinoid drug for the treatment of chronic insomnia. The company also provides over the counter (OTC) products, including SprinJeneCBD, an oral care product; and acne treatment products under the RAF FIVE name, as well as Zyraydi, an enhanced distillate capture and dissolution matrix technology. In addition, it offers products for autism and chronic noncancer pain. The company was formerly known as Zelda Therapeutics Limited and changed its name to Zelira Therapeutics Limited in December 2019. Zelira Therapeutics Limited was incorporated in 2003 and is based in Perth, Australia.

Company Details

  • SectorHealthcare
  • IndustryBiotechnology
  • CEODr. Oludare Odumosu
  • Employees0
  • Headquarters101 St Georges Terrace, Perth, WA, Australia, 6000, Australia
  • Websitehttps://zeliratx.com

Leadership

  • Mr. Osagie O. Imasogie Esq.Founder & Chairman · b. 1962
  • Dr. Oludare OdumosuMD, Global CEO & Director
  • Mr. Greg BlakeExecutive Director
  • Mr. Timothy Ryan SlateCompany Secretary & Non-Executive Director
  • Mr. Rahul GanesanVice President of Finance & Accounting
  • Dr. Patty WasherClinical Trial Consultant

Financials

Income Statement

Currency: AUD2004-06-302005-06-302006-06-302007-06-302008-06-302009-06-302010-06-302011-06-302012-06-302013-06-302014-06-302015-06-302016-06-302017-06-302018-06-302019-06-302020-06-302021-06-302022-06-302023-06-302024-06-302025-06-30
Total Revenue501.04K569.48K140.69K21.08M23.00K129.00K34.25K498.00K29.00K29.00K21.00K11.59K2.73K167.76K561.39K859.17K663.32K663.32K1.54M301.12K94.95K656
Growth (%)-+13.66%-75.29%+14882.59%-99.89%+460.87%-73.45%+1354.01%-94.18%0.00%-27.59%-44.81%-76.45%+6045.05%+234.64%+53.04%-22.80%0.00%+132.26%-80.45%-68.47%-99.31%
Cost of Revenue141.29K178.19K70.66K-3.85M-733.00K46.00K44.00K7.00K5.00K12.00K12.00K36.00K00-275.05K702.48K7.26M3.52M84.67K803.60K
Gross Profit359.75K391.29K70.03K24.93M--34.25K--29.13K20.74K8.91K300.00K100.04K313.76K859.17K-275.05K-39.16K-5.72M-3.22M10.28K-802.95K
Gross Margin71.80%68.71%49.78%118.25%--100.00%--100.46%98.75%76.84%10989.01%59.63%55.89%100.00%-41.47%-5.90%-371.02%-1068.03%10.83%-122400.15%
Operating Expense1.04M860.64K1.34M46.55M--1.15M--351.20K315.92K432.73K1.18M6.42M3.14M5.10M7.56M9.61M7.70M4.20M5.95M3.15M
Operating Income-677.84K-469.35K-1.27M-21.62M-487.99K-1.85M-1.12M-463.08K-630.63K-322.06K-295.18K-423.83K-876.42K-6.32M-2.83M-4.24M-7.84M-9.65M-13.41M-7.41M-5.94M-3.95M
Operating Margin-135.29%-82.42%-900.08%-102.58%-2121.71%-1437.74%-3258.59%-92.99%-2174.58%-1110.56%-1405.60%-3656.84%-32103.33%-3769.95%-503.78%-493.31%-1181.72%-1455.13%-870.75%-2461.74%-6253.93%-602467.84%
EBITDA1.45K-402.82K-1.22M-34.89M-487.99K-20.22M-1.10M18.57K-624.00K-306.63K-289.88K-423.83K-876.42K-3.71M635.41K-4.23M-7.71M-9.41M-13.06M-6.79M-36.44M-4.17M
EBITDA Margin0.29%-70.73%-867.45%-165.50%-2121.71%-15674.22%-3209.05%3.73%-2151.72%-1057.34%-1380.40%-3656.84%-32103.33%-2214.18%113.18%-491.99%-1162.26%-1418.71%-847.93%-2254.79%-38378.53%-636296.65%
Net Income-25.58K-311.67K-901.34K-38.16M12.61M-20.27M-1.69M7.03K-637.96K-311.84K-290.22K-400.08K-898.64K-6.16M-1.73M-2.90M-7.02M-8.55M-11.95M-5.57M-36.57M-3.63M
Net Income Margin-5.10%-54.73%-640.65%-181.04%54845.95%-15713.81%-4928.45%1.41%-2199.86%-1075.32%-1381.99%-3451.94%-32917.11%-3670.37%-308.13%-337.21%-1057.57%-1288.84%-775.35%-1850.75%-38513.04%-553029.27%
R&D---2.66M-------90.22K14.13K668.41K1.79M2.33M3.69M2.08M1.40M1.34M2.81M2.66M
R&D as % of Total Revenue---12.64%-------778.43%517.55%398.43%319.26%270.90%556.55%313.74%90.66%443.82%2959.60%406189.48%
Interest Expense164.83K203.13K102.20K034.25K000000000012.34K42.63K53.85K76.66K739.27K407.21K
Interest Expense % of Total Revenue0.00%0.85%144.38%0.48%0.00%26.55%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%1.86%6.43%3.50%25.46%778.57%62075.15%

Balance Sheet

Currency: AUD2004-06-302005-06-302006-06-302007-06-302008-06-302009-06-302010-06-302011-06-302012-06-302013-06-302014-06-302015-06-302016-06-302017-06-302018-06-302019-06-302020-06-302021-06-302022-06-302023-06-302024-06-302025-06-30
Total Assets8.54M10.02M26.45M9.27M1.40M3.55M694.95K875.29K1.43M1.08M780.16K408.27K87.52K7.97M6.31M3.52M35.79M39.37M37.70M33.89M5.18M1.30M
Total Liabilities252.17K143.06K11.58M24.12M123.06K1.07M40.63K213.94K79.21K38.12K30.01K50.40K290.42K70.63K99.42K407.24K1.24M1.54M2.01M2.18M9.36M5.59M
Total Equity8.29M9.88M14.88M-14.84M1.28M2.48M654.33K661.35K1.35M1.04M750.16K357.87K-202.91K7.90M6.21M3.11M34.55M37.83M35.20M31.80M-4.51M-4.46M
Cash2.15M1.46M1.96M228.94K1.09M2.71M343.36K787.96K1.28M969.30K597.53K324.60K55.69K7.87M5.69M3.07M1.70M4.97M2.75M146.21K586.16K5.66K
Total Debt--3.00M3.32M-798.36K------1.00M--632.32K632.32K551.08K500.91K437.90K5.95M2.14M
Net Debt-2.15M-1.46M1.04M3.09M-1.09M-1.91M-343.36K-787.96K-1.28M-969.30K-597.53K-324.60K944.31K-7.87M-5.69M-3.07M-1.06M-4.42M-2.25M291.70K5.36M2.14M

Cash Flow

Currency: AUD2004-06-302005-06-302006-06-302007-06-302008-06-302009-06-302010-06-302011-06-302012-06-302013-06-302014-06-302015-06-302016-06-302017-06-302018-06-302019-06-302020-06-302021-06-302022-06-302023-06-302024-06-302025-06-30
Operating Cash Flow-2.75M-2.56M-7.09M-14.81M-2.21M-1.57M-1.18M101.92K-572.82K-259.89K-276.25K-292.89K-331.82K-2.20M-2.62M-3.34M-6.94M-8.62M-9.43M-7.25M-4.39M-4.91M
Investing Cash Flow-1.69M-29.63K-324.90K-235.72K-2.21M-674.57K-29.13K370.99K-17.91K-30.41K-79.74K-292.89K-250.00K158.83K422.82K731.62K1.11M1.38M-207.78K2.83M919.74K1.15M
Financing Cash Flow5.70M1.90M7.91M13.31M3.08M3.68M-900.00K-1.12M7.79K7.79K7.79K337.86K9.19M20.00K4.50M4.50M10.53M7.10M1.77M3.92M3.19M
Capital Expenditure1.06M75.08K324.90K235.72K074.57K131.62K13.95K17.91K30.41K79.74K07.08K7.08K28.23K28.23K15.97K44004
Free Cash Flow-3.81M-2.64M-7.41M-15.05M-2.21M-1.65M-1.31M87.98K-590.73K-290.30K-355.99K-292.89K-331.82K-2.21M-2.62M-3.37M-6.95M-8.62M-9.43M-7.25M-4.39M-4.91M
Dividends Paid--2.80M11.12M--------08.58M--------
FCF to OCF138.39%102.93%104.58%101.59%100.00%104.75%111.13%86.31%103.13%111.70%128.86%100.00%100.00%100.32%100.00%100.84%100.23%100.00%100.00%100.00%100.00%100.00%
Dividend Paid to FCF---37.77%-73.89%--------0.00%-388.70%--------

Earnings

Report DateMar 18, 2016Sep 23, 2016Feb 3, 2017Aug 31, 2017Feb 27, 2018Aug 31, 2018Feb 22, 2019Aug 30, 2019Feb 28, 2020Aug 28, 2020Feb 22, 2021Aug 30, 2021Feb 23, 2022Sep 7, 2022Feb 28, 2023Feb 26, 2025Aug 29, 2025
EPS Estimate0.000.000.000.000.000.000.000.000.000.000.000.00-0.35-0.00-0.350.000.00
EPS Actual-0.010.00-0.020.000.000.000.000.000.000.000.000.000.00-0.70-0.34-0.21-0.10
Surprise------------100.00%-69900.00%2.86%--
Timing-------------Pre-marketAfter-hours--

Key Statistics & Ratios

Market Cap6.57M
Enterprise Value8.08M
Trailing P/E0.00
Forward P/E5.78
Price / Sales10020.70
Price / Book0.32
EPS-0.32
Book Value-0.375
Revenue (TTM)656
Gross Profit (TTM)-802.95K
EBITDA-4.17M
Profit Margin0.00%
Operating Margin-658713.13%
Return on Equity-266.82%
Return on Assets-83.30%
Shares Outstanding13.15M
Shares Float6.01M
Beta0.61
Dividend Yield0.00%
Dividend Rate0.00
Payout Ratio0.00%

Stock Splits

  • Apr 14, 20221:175
  • Oct 17, 20161:5
  • Apr 11, 20126:5
  • Oct 2, 20081:11
  • Mar 6, 20081:5
  • Apr 7, 200517:16
  • Apr 15, 200464:63